الفهرس 
Ulcerative colitis
Lipocalin-2 (LCN2)Only 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Background: Ulcerative colitis is a chronic inflammatory disease of the colon, that is characterised by attacks of remission and exacerbations, The diagnosis is suspected clinically and confirmed through endoscopic biopsy, it needs to be followed up and assessed by non-invasive biomarkers, one of these biomarkers is fecal calprotectin. Recently B cell-activating factor (BAFF), a new biomarker, has been proposed to be a regulator of B cell and T cell immune responses and be associated with inflammatory processes in autoimmunity and B cell malignancies.
Aim: To investigate the role of faecal BAFF in monitoring activity of Ulcerative Colitis.
Patients and methods: 50 Egyptian patients with ulcerative colitis were divided into 2 groups: group 1 including 40 patients with active UC and group 2 including 10 patients with inactive UC, disease activity was measured according to the Mayo activity scoring index, fecal BAFF and fecal Calprotectin were measured for all subjectcs using ELISA.
Results: Fecal BAFF was significantly increased in patients with active UC (group 1) in comparison with inactive UC patients (group 2) with mean value of 2.69 ± 0.48, 1.63 ± 0.25, respectively, p value> 0.001. And that the cut-off value of 120 mg/l indicating the presence of active disease, with a sensitivity of 92% and a specificity of 100%. In comparison with fecal Calprotectin, fecal BAFF is more sensitive and specific for monitoring activity of UC patients.
Conclusion: Correlations of faecal BAFF to Mayo activity scoring index were both higher than that of faecal calprotectin, implying that faecal BAFF could be a good indicator for overall evaluation of mucosal inflammation combining severity and extent. So, faecal BAFF has a better performance as compared with faecal calprotectin in evaluation of intestinal inflammation in UC. Faecal BAFF is a simple and non-invasive marker that can be helpful for differentiating active UC from inactive disease and a good guide for mucosal inflammation.
Background: Ulcerative colitis is a chronic inflammatory disease of the colon, that is characterised by attacks of remission and exacerbations, The diagnosis is suspected clinically and confirmed through endoscopic biopsy, it needs to be followed up and assessed by non-invasive biomarkers, one of these biomarkers is fecal calprotectin. Recently B cell-activating factor (BAFF), a new biomarker, has been proposed to be a regulator of B cell and T cell immune responses and be associated with inflammatory processes in autoimmunity and B cell malignancies.
Aim: To investigate the role of faecal BAFF in monitoring activity of Ulcerative Colitis.
Patients and methods: 50 Egyptian patients with ulcerative colitis were divided into 2 groups: group 1 including 40 patients with active UC and group 2 including 10 patients with inactive UC, disease activity was measured according to the Mayo activity scoring index, fecal BAFF and fecal Calprotectin were measured for all subjectcs using ELISA.
Results: Fecal BAFF was significantly increased in patients with active UC (group 1) in comparison with inactive UC patients (group 2) with mean value of 2.69 ± 0.48, 1.63 ± 0.25, respectively, p value> 0.001. And that the cut-off value of 120 mg/l indicating the presence of active disease, with a sensitivity of 92% and a specificity of 100%. In comparison with fecal Calprotectin, fecal BAFF is more sensitive and specific for monitoring activity of UC patients.
Conclusion: Correlations of faecal BAFF to Mayo activity scoring index were both higher than that of faecal calprotectin, implying that faecal BAFF could be a good indicator for overall evaluation of mucosal inflammation combining severity and extent. So, faecal BAFF has a better performance as compared with faecal calprotectin in evaluation of intestinal inflammation in UC. Faecal BAFF is a simple and non-invasive marker that can be helpful for differentiating active UC from inactive disease and a good guide for mucosal inflammation.